Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.47
(
-1.18%
)
Bitcoin
74,645.97
(
0.95%
)
News Focus
News Focus
Post# of 30493
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech_researcher post# 8397

Wednesday, 04/30/2014 10:40:15 PM

Wednesday, April 30, 2014 10:40:15 PM

Post# of 30493

Do you have an investment thesis in mind to leverage off of the diabetes growth in China and India? Not a clear pathway for this that I can see.

I own ABT, which is the #2* drug company in India, although it’s not a direct play on type-2 diabetes. For several years, I’ve wanted to own NVO, but I never pulled the trigger because I thought the valuation was too high.

*ABT is technically still #1 in India until the Sun-Ranbaxy merger closes.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now